CHAPTER 9

The Antigenome: From Protein Subunit Vaccines to Antibody Treatments of Bacterial Infections?
Carmen Giefing, Eszter Nagy and Alexander von Gabain*

Abstract

New strategies are needed to master infectious diseases. The so-called "passive vaccination", i.e., prevention and treatment with specific antibodies, has a proven record and potential in the management of infections and entered the medical arena more than 100 years ago. Progress in the identification of specific antigens has become the hallmark in the development of novel subunit vaccines that often contain only a single immunogen, frequently proteins, derived from the microbe in order to induce protective immunity. On the other hand, the monoclonal antibody technology has enabled biotechnology to produce antibody species in unlimited quantities and at reasonable costs that are more or less identical to their human counterparts and bind with high affinity to only one specific site of a given antigen. Although, this technology has provided a robust platform for launching novel and successful treatments against a variety of devastating diseases, it is up till now only exceptionally employed in therapy of infectious diseases. Monoclonal antibodies engaged in the treatment of specific cancers seem to work by a dual mode; they mark the cancerous cells for decontamination by the immune system, but also block a function that intervenes with cell growth. The availability of the entire genome sequence of pathogens has strongly facilitated the identification of highly specific protein antigens that are suitable targets for neutralizing antibodies, but also often seem to play an important role in the microbe's life cycle. Thus, the growing repertoire of well-characterized protein antigens will open the perspective to develop monoclonal antibodies against bacterial infections, at least as last resort treatment, when vaccination and antibiotics are no options for prevention or therapy. In the following chapter we describe and compare various technologies regarding the identification of suitable target antigens and the foundation of cognate monoclonal antibodies and discuss their possible applications in the treatment of bacterial infections together with an overview of current efforts.

Introduction

Infectious diseases remain a major threat against human life. Microbial infections are still out of control in many parts of the less developed world where they count for most of the deaths, but also cause an often underestimated toll of death (e.g., community acquired Pneumococcal diseases and Pseudomonas infections in patients in intensive care), life-long mutilation (infertility due to Chlamydia trachomatis), medical complication due to nosocomial infections caused most often by Staphylococcus aureus, Enterococcus faecalis, Klebsiella ssp and fungi. It is estimated that nosocomial infections annually add US$5-10 billion to the cost of the national healthcare system in the United States. Apart from infections caused by viruses and protozoa that only in specific instances can

*Corresponding Author: Alexander von Gabain—Intercell AG, Campus Vienna Biocenter 2, A-1030, Vienna, Austria. Email: agabain@intercell.com

Pharmaceutical Biotechnology, edited by Carlos A. Guzmán and Giota Z. Feuerstein. ©2009 Landes Bioscience and Springer Science+Business Media.
be treated with suitable pharmaceuticals, the emergence of antibiotic-resistant strains of nearly all kinds of bacterial pathogens in the community and in hospitals is occurring at an increasingly alarming rate. The increase of nosocomial infections, the comeback of bacterial infections in immune suppressed individuals, e.g., TB in AIDS patients, and the lately appeared scenario of bio-terrorism, e.g., in the context of anthrax, are reminders that new strategies are needed to master infectious diseases in prophylactic and therapeutic settings.

Vaccination is undeniable the most successful medical intervention in the control of infectious diseases. However, since vaccine-induced immune protection against specific microbes takes more than a couple of weeks to develop and postexposure vaccination is only exceptionally a useful tool, combination with passive immunization is indispensable (e.g., treatment against the rabies virus, reviewed in ref. 7), when instant protection or treatment is required. Therapeutic vaccines are still in the exploratory stage of development and more prone to find their application in the treatment of chronic infectious diseases, rather than to become an immediate measure against a sudden infectious threat. On the other hand, most vaccines seem to confer protective immunity to the vaccinated individuals by the means to induce specific antibodies that capture the invading microbe, prior it had an opportunity to colonize in the exposed host. The so-called "passive vaccination," i.e., prevention and treatment with specific antibodies, has a proven record and potential in the management of infections.

Already the pioneers of early microbiology and immunology in the late 19th century, led by their prominent proponents, Emile Roux and Emil von Behring, have realized the concept of "passive vaccination"; namely that sheep and horses inoculated with filterable toxin extracts derived from Corynebacterium diphtheriae cultures were able to mount an "anti-toxin" in their blood. Serum derived from the animals' blood was able to rescue children in the lethal stage of the infection caused by the same pathogen. Revisiting this historical landmark therapy of diphtheria, it was realized that the "anti-toxin" in the serum of inoculated animals is synonymous with a protein species coined today antibodies and the "toxin" with a virulence factor secreted by the pathogen during infection. Thus, the remarkable and groundbreaking therapy concept explored more than 100 years ago, has paved the way to "passive immunization," i.e., all kind of serum-treatments that have found their broad medical applications in prevention e.g., viral infections or in emergency treatments against e.g., snake venoms. Serum antibodies against microbes and even isolated antigens, like the diphtheria toxin, are polyclonal, meaning that they bind—in case of a specific antigen molecule—to a variety of sites or—in case of a microbe—to multiple surface structures.

The advent of the monoclonal antibody technology launched by Georg Kohler and Cesar Milstein nearly 30 years ago, has enabled biotechnology to engineer specific antibody species that bind with high affinity to only one specific site of a given antigen and can be produced in unlimited quantities. Follow-up technologies made it possible to produce monoclonal antibodies that are more or less identical to their human counterparts, employing microbial and tissue culture resources for manufacturing. During the last decade, monoclonal antibodies have infiltrated the therapeutic arena with great success and thereby provided a plethora of novel treatments against a variety of typically devastating diseases including specific cancers, autoimmune diseases and other pathological conditions. The common denominator of all monoclonal antibodies used in therapy is to bind to highly specific sites of typically well characterized protein targets and thereby intervene with biological functions involved in the pathogenic condition; e.g., to growth hormone receptors expressed at the surface of malignant cells. Interestingly, monoclonal antibodies engaged in the treatment of specific cancers seem to work by a dual mode; they mark the cancerous cells for decontamination by the immune system, but also block a function that intervenes with cell growth.

Progress in the identification of specific antigens has become the hallmark in the development of novel subunit vaccines that only contain single specific structures derived from the microbe in order to induce protective immunity. The first viral subunit vaccine on the market that has become a great success is directed against Hepatitis B virus and based on recombinant protein
technology. Also pathogen-specific glycosides coupled to carrier proteins are successfully used in so-called conjugated vaccines directed against bacterial infections; an example is "Prevnar" a registered vaccine against Pneumococcus. The successful development of subunit vaccines comprising isolated microbial components as antigens has supported the notion that antibodies per se, may suffice to neutralize pathogens in the body even in a setting of "passive vaccination". So far only one anti-infective monoclonal antibody, which is directed against the Respiratory Syncytial Virus (RSV) (Palivizumab), has entered the therapeutic arena. A number of anti-infective antibodies based on specific antigens against bacterial infections are in the stage of clinical and preclinical development (Table 1).

The availability of the entire genome sequence of pathogens and subsequently the application of proteome and genome based technologies have facilitated the identification of highly specific protein antigens suited for the development of novel bacterial subunit vaccines. One of the recently described methods designed to comprehensively mine bacterial genomes for protective antigens, has taken advantage of antibodies derived from humans who have encountered the target pathogen with positive outcome. The sum of all protein antigens that are recognized by cognate antibodies from individuals exposed to the pathogen has been defined as antigenome. Typically the antigenome comprises 100 to 200 antigens. Applying a number of selective filters and criteria to the antigenome, in vitro validation makes it possible to reduce the number of best-suitable candidate antigens for vaccine development to about 15 to 30 (unpublished data). Such antigens are presently tested in advanced preclinical and early clinical trials (Kuklin et al. and unpublished data). The availability of bacterial protein antigens with promising profiles for vaccine design, but also the identification of specific host targets, have provided novel gates to develop monoclonal antibodies for protection and treatment against specific infectious diseases. In the following chapter we will discuss the impact of discovery and characterization of specific antigens on the development of novel vaccines and antibody treatments.

A New Paradigm in Bacterial Vaccine Development

The capability of the human immune system to identify and eliminate pathogens and pathogen-infected cells is the cornerstone of immunization, the most effective strategy to prevent infectious disease. However, vaccines are still not available against major pathogens including Meningococcus serogroup B, Gonococcus, Helicobacter pylori and Shigella. Traditional vaccines are mainly based on inactivated or attenuated microbes or more recently on polysaccharides of a particular pathogen. Due to the fact that such vaccines cannot prevent numerous diseases, or even worse, induce severe side effects, novel and defined vaccines are being developed to overcome these limitations. Improved vaccines are needed to combat diseases for which current vaccines are inadequate (e.g., tuberculosis) or against pathogens that had not been on the target list for immunization, such as Staphylococci and Enterococci both with an enormous potential to develop drug resistance. The recently emerging threat of bioterrorism boosts the need for new vaccines further.

Most of the new generation vaccines comprise subunits of pathogens (purified protein, toxoid, polysaccharide with or without conjugation) and have made major headways in controlling serious diseases. At present, there are only two vaccines based on recombinant proteins (against Hepatitis B and Lyme disease) that are shown to be effective in preventing human infections. Nevertheless, protein based recombinant vaccines are considered to be the most promising approach to meet the demands of future vaccinology.

In order to design novel subunit vaccines, the proper antigens have to be identified and subsequently evaluated in experimental animal models mimicking human diseases. While vaccine development for obligate pathogens with well-defined virulence mechanisms has progressed well, those bacteria that are in the focus of current vaccine efforts (e.g., opportunistic pathogens and those with multiple serotypes) have more complex pathogenesis.

Vaccinologists are witnessing a remarkable revolution in technologies that now contribute to rapid identification of novel vaccine components against many important human pathogens.
| Drug         | Pathogen | Antigen Target                                      | Type of Antibody                                                                 | Highest Phase | Originator              | Indication                                                                 |
|-------------|----------|-----------------------------------------------------|-----------------------------------------------------------------------------------|---------------|-------------------------|---------------------------------------------------------------------------|
| Aurograb™   | S. aureus| ABC transporter                                     | Human-derived single chain variable fragment (scFv) therapeutic antibody          | III           | NeuTec Pharma           | Methicillin-resistant S. aureus infections                                 |
| Altastaph™ | S. aureus| S. aureus Type 5 and Type 8 polysaccharides         | Polyclonal (5% Ig prepared from donors immunized with StaphVAX™)                 | II            | Nabi Biopharmaceuticals | Staphylococcal infections                                                 |
| Pagibaximab | Staphylococcus spp. | Lipoteichoic acid (LTA) S. epidermidis | Chimeric mAb                                                                     | II            | Eli Lilly/Biosynexus     | Staphylococcal infections                                                 |
| Aurexis™    | S. aureus| S. aureus ClfA                                      | Humanised mAb                                                                     | II            | Inhibitex               | Treatment—in combination with standard-of-care antibiotics—of serious S. aureus infections in hospitalized patients |
| Veronate™   | S. aureus| Staphylococcal fibrinogen-binding proteins SdrG and ClfA (MSCRAMM) | Human polyclonal                                                                | Preregistration | Inhibitex               | Staphylococcal infections in VLBW (very low birth weight) infants: Prevention of hospital-associated infections in premature infants weighing less than 1,250 grams |

*continued on next page*
**Table 1. Continued**

| Drug        | Pathogen     | Antigen Target       | Type of Antibody                                                                 | Highest Phase | Originator                        | Indication                                      |
|-------------|--------------|----------------------|----------------------------------------------------------------------------------|---------------|-----------------------------------|------------------------------------------------|
| ETI 211     | *S. aureus*  | *S. aureus* protein A| Antibody conjugate: anti-human complement receptor Type-1 mAb chemically cross-linked with an anti-*S. aureus* protein A mAb | Preclinical   | Elusys Therapeutics               | Methicillin-resistant *S. aureus* infections   |
| *S. aureus* mAb | *S. aureus*  | IsdB                 | Fully human mAbs                                                                | Preclinical   | Merck/Intercell                   | Staphylococcal infections                      |
| SdrG mAb    | *S. epidermidis* | SdrG-fibrinogen-binding MSCRAMM protein | Human polyclonal                                                                  | Preclinical   | Inhibitex                        | *S. epidermidis* infections                    |
| Enterococcal mAb | *Enterococcus* | MSCRAMM* proteins | Fully human mAbs                                                                | Preclinical   | Inhibitex/Dyax                   | Drug-resistant enterococcal infections          |
| IC 47       | *S. pneumoniae* | Surface proteins     | Fully human mAbs                                                                | Preclinical   | Kirin/Intercell                  | Pneumococcal infections in immunocompromised patients |
| KBPA 101    | *P. aeruginosa* | Directed against pseudomonal serotypes | Fully human mAbs                                                                | II            | Kenta Biotech                    | Pseudomonal infections                          |
| Anti-P. *P. aeruginosa* mAbs | *P. aeruginosa* | Natural human immune response | Fully human mAbs                                                                | I             | Berna Biotech                    | Pseudomonal infections                          |
| Anti-P. *P. aeruginosa* mAbs | *P. aeruginosa* | Undisclosed | Fully human mAbs                                                                | Preclinical   | Millenium Biologix Corporation | Pseudomonal infections                          |

*continued on next page*
| Drug       | Pathogen       | Antigen Target | Type of Antibody | Highest Phase | Originator                                      | Indication                                      |
|------------|----------------|----------------|------------------|---------------|------------------------------------------------|------------------------------------------------|
| MDX 066    | *Clostridium difficile* | Toxin A       | Fully human mAbs | II            | Medarex, University of Massachusetts Medical School | *C. difficile infections*, *Diarrhea*            |
| MDX 1388   | *C. difficile*  | Toxin B        | Undisclosed      | Preclinical   | Medarex, MBL                                     | *C. difficile infections*                      |
| DiffCAM™   | *C. difficile*  | *C. difficile* toxins | Bovine immunoglobulins | I            | ImmuCell                                         | *C. difficile infections*                      |
| Anti-botulism neurotoxin mAbs | *Clostridium botulinum* | Type A-botulinum neurotoxin | mAbs | Preclinical | XOMA                                             | Biological agents used in bioterrorism          |
| Urtoxazumab | Shiga-like toxin-producing *E. coli* | B-subunit of shiga-like toxin | Recombinant humanised mAbs | II            | Teijin Pharma                                   | haemolytic uraemic syndrome                     |
| Raxibacumab | *B. anthracis* | *B. anthracis* protective antigen | Fully human mAbs | I            | Human Genome Sciences                             | Anthrax                                        |
| Valortim™  | *B. anthracis* | *B. anthracis* protective antigen | Fully human mAbs | I            | Medarex                                         | Anthrax                                        |
| Anthim™    | *B. anthracis* | *B. anthracis* protective antigen | Heteropolymer chemically linked mAb | I            | Elusys Therapeutics                              | Anthrax                                        |
| Afelimomab  | Septic shock   | human TNFα     | Murine mAbs      | III           | Abbott GmbH & Co. KG                             | Septic shock                                   |
| Anti-TNFα  | Septic shock   | human TNFα     | Sheep polyclonal | II            | Protherics                                       | Septic shock (among others)                    |

Data were collected from the Adis R&D Insight database and homepages of listed companies in July 2006 using the world wide web. Antibodies were sorted according to antigen target: first, antibodies targeting pathogen surface structures are listed, followed by anti-toxin antibodies and last antibodies against TNFα. Monoclonal Antibodies are abbreviated with mAbs. This is not a complete list.
The availability of complete genome sequences of pathogens has dramatically changed the perspectives for developing improved and novel vaccines by increasing the speed of target identification. Genomics-based technologies have many advantages compared to conventional approaches, which are time-consuming and usually identify only abundant antigens expressible under in vitro culture conditions. Strategies based on genomics have made major contributions to the identification and selection of novel vaccine candidates to combat bacterial infections by exploiting genome sequence information in alliance with adjunct technologies, including in silico prediction (bioinformatics), expression analyses (random mutagenesis, microarrays, in vivo expression technologies), or protein/peptide based selection methods (proteomics and immuno-selection using peptide expression libraries). Although, most technologies can be readily applied to most pathogens, certain strategies are more suitable than others due to distinct advantages and limitations.

The most promising candidate antigens have to be (1) expressed during human disease; (2) accessible (surface bound or secreted) for functional antibodies or effector immune cells; (3) conserved among strains; (4) essential for in vivo survival in order to avoid counter selection; and (5) protective in animal models mimicking the relevant human disease. There is no technology available today that can select antigen candidates fulfilling all five attributes. However, a comprehensive selection procedure meeting the key criteria can be combined with a validation screening that addresses the remaining requirements.

To date, approximately 300 pathogen genome sequences have been determined (http://www.tigr.org/cmr). Genome sequences of bacterial pathogens contain an average of 2700 genes, thus appropriate selection criteria have to be applied to reduce the number of antigen candidates for empirical testing. Bioinformatics has been successfully employed for the prediction of candidate antigens of extracellular pathogens, due to the specific features easing the prediction of cell surface and secreted proteins and/or the identification of genes that show sequence and/or structural homology to known virulence factors. This type of genome-based systematic search for vaccine candidates was termed "reverse vaccinology." The validity of this approach was first confirmed by the identification of protective antigens from Meningococcus serogroup B and later from Pneumococcus (reviewed in ref 27). "Reverse vaccinology in silico prediction" typically targets up to 25% of all genome-encoded proteins and, thus, necessitates subsequent high through-put cloning and recombinant protein expression. Inclusion of more restrictive selection criteria became possible through the availability of several genomes for individual pathogenic species. Comparative genomics is another suitable tool to identify genes shared among species of related pathogens or, alternatively, to identify genes present only in pathogenic, but not in attenuated or naturally nonpathogenic strains or species. Such approaches have been successfully applied to Group A Streptococcus and Mycobacterium.

The hallmark of effective vaccine antigens is their ability to induce antibodies and/or to activate immune cells. Regarding this feature, in silico prediction of antigenicity is still in infancy. It is anticipated that with the wealth of knowledge currently being generated, it will be possible to develop prediction algorithms to pinpoint proteins likely to be immunogenic and/or protective. More advanced is the strategy to mine genomic sequence databases of intracellular pathogens for predicted T-cell epitopes and validate them experimentally based on immune recognition. Despite all successes, the bioinformatic genome mining approach has limitations due to the inaccuracy of available algorithms, regarding the prediction of (1) open-reading frames that encode proteins; (2) surface and secreted proteins; (3) gene function based on homology searches. Moreover, it is almost impossible to predict the conditions under which candidate antigens are expressed, unless the genes are equipped with well-defined regulatory sequences and promoters.

The availability of complete pathogen genome sequences stimulated the development and wide-spread application of high density DNA-arrays. Comparative microarray analysis identifies genomic diversity and conservation patterns among bacteria. The development of vaccines cross-protective among serotypes and variants of pathogenic species specifically profits from this
analysis, as it was demonstrated by the identification of common genes and protective antigens from major serotypes of Streptococcus agalactiae.34,35

Profiling of genomic expression with microarrays has revolutionized the analysis of genes involved in microbial pathogenesis (reviewed in ref. 36). Considering its value in vaccine development, the emphasis is focused on pathogen-host interactions. In several studies novel vaccine candidates were identified, based on requirement for infectious state and dissemination, adhesion or evasion of innate defense mechanisms.37-42 This approach—that heavily relies on genome annotation and bioinformatics—is most powerful in providing a global view on integrated cellular processes active during infection. Again, it has to be followed by combined application of gene cloning, recombinant protein technology and in vitro functional assays to validate target selection for vaccine development.

Proteome analysis has rapidly developed in the postgenome era and is now widely accepted as a complementary technology to genetic profiling (reviewed in ref. 41). The most direct way of using proteomics technologies for antigen identification is the combination of conventional proteome analysis with serology. There have been a number of recent studies investigating the “immunoproteome” of important human pathogens (for an example see Haas et al42). Combining “reverse genomics” and proteomics is especially useful for confirmation of bioinformatic prediction of ORFs and surface location. Moreover, a strong asset of proteomic studies is the identification of surface located proteins that cannot be predicted by bioinformatic means.43,44 Serological proteome analysis of enriched membrane and cell wall fractions from several pathogens, such as S. aureus, Bacillus anthracis and S. agalactiae has indeed demonstrated to identify novel surface antigens and protective vaccine candidates without sequence features that could have been recognized by in silico prediction algorithms.45-47

The design of proteome-based studies has to be carefully performed, since there is an inherent risk to preferentially detect abundant proteins and to miss those that are expressed only under in vivo conditions and have lower solubility (e.g., membrane and surface proteins). Another need, not necessarily met by proteome analysis, is that protective vaccine components have to be derived from proteins expressed under disease conditions against which prevention is directed. As many virulence factors and antigens are only expressed in vivo, approaches that solely rely on in vitro grown bacteria are likely to miss important protective antigens.

Evaluation of immune responses against any candidate antigen is a crucial validation task and cannot be circumvented. Therefore, techniques using human immunogenicity as their primary screening and selecting parameter on a genome-wide basis seem to be especially valuable for vaccine development. Recently a novel approach combining the advantages of full genome coverage and serological antigen identification was published. The method was first applied to the genome-wide identification of in vivo expressed antigens from S. aureus by using antibodies from human serum and comprehensive small-fragment genomic surface display libraries.22 Subsequently, the technology was extended with an integrated approach for antigen validation as selected clones are directly subjected to generation of epitope-specific immune sera for surface localization and in vitro functional assays. This feature allows the analysis of antigens without the demanding task of high through-put recombinant protein production. This method, named antigenome technology, has been extended to many important human pathogens and validated by the discovery of novel and highly protective antigens, in addition to the identification of the majority of the ones that have been previously described.20 Since the antigenome technology provides a subset of all genome-encoded proteins, which are expressed by the pathogen in vivo and induce antibodies in humans, the identified antigens fulfill major requirements of vaccine candidate antigens. It is interesting to note that the antigens confined by the antigenome seem often to be involved, as secreted and surface bound proteins, in virulence functions and, thus, being attributed to the “pathosphere” that has been defined as the growing gene pool in which pathogens meet and mingle to cause diseases.48 It is observed that many of the identified antigens from various pathogens were not or only very weakly expressed under in vitro growth conditions, indicating that a proteomic approach that preferentially selects abundant proteins would likely fail to identify them. As the bioinformatic genome mining approach depends on the accuracy
of available algorithms, potential vaccine candidates can be missed due to a misleading or not existing annotation. Based on the analysis of the antigenomes of fifteen pathogens, approximately 25% of all identified antigenic proteins can only be assigned to hypothetical proteins or proteins with unknown function. Many of the identified antigens would, thus, be not be found by a bioinformatic approach. The cumulative data obtained for the fifteen antigenomes showed that a large fraction of the antigens identified by this method represents cell surface or secreted proteins. Nearly fifty percent of all antigens fell into four cellular role categories: cell wall, cellular processes, transport and binding proteins and determinants of protein fate. In order to pinpoint candidates for vaccine development, a comprehensive and rapid validation strategy to retrieve the most promising antigens from the 100-200 antigens was implemented. Clones selected from peptide display libraries are directly subjected to generation of epitope-specific immune sera used for testing of surface localization and in vitro bactericidal assays. The human immunogenicity of identified antigens is evaluated with synthetic peptide epitopes. The application of these major selection criteria combined with traditional gene conservation studies reduces the antigenome to a small number of candidate proteins that can be rapidly expressed in recombinant form for subsequent in vivo studies. The re-identification of most of the previously identified protective antigens of Staphylococci and Streptococci, such as PspA, M1 protein, Sip and ClfA gives further supports the power of the antigenome technology. Most importantly, novel protective proteins yielding animal protection in animal vaccine models, were found in the prioritized groups of antigens derived e.g., from S. aureus and Streptococcus pneumoniae (unpublished data), respectively. Thus, the utilization of protective antigens—included in subunit vaccines—as targets for monoclonal antibodies, provides an attractive strategy to develop novel treatments against life threatening infections. Such a notion is supported by recent data showing that protection can be conferred to naïve animals, using serum directed against target antigens that have been validated in vaccine models (Nagy et al, personal communication).

The Advent of Monoclonal Antibodies in Disease Treatment

The renaissance of antibody therapy since the mid-1990s was mainly possible through significant improvements in antibody generation and purification (Fig. 1). The first step towards nowadays production technologies was the description of the unlimited generation of monoclonal antibodies by Georges Koehler and Cesar Milstein in 1975,49 for which they were awarded the Nobel Prize in 1984. They fused mouse myeloma cells with normal antibody-producing splenic B-cells isolated from mice that were immunized with sheep red blood cells as antigen. The resulting hybridoma cells possessed the immortal propagation potential of the myeloma cells and secreted large quantities of monoclonal antibodies. Selected clones could then be cultured indefinitely and secreted large quantities of monoclonal antibodies.

Despite their success as research tools, mouse monoclonal antibodies as human therapeutics are limited for various reasons. The main problem is the high immunogenicity of these foreign proteins in humans resulting in fast clearance (short half life) and toxicity by human anti-mouse antibodies (HAMAs).50 Moreover, mouse antibodies have a reduced effect in human recipients due to their nonoptimal interactions with human complement and Fc receptors.51

In the early 1980s strategies for chimerization and humanization were ensued to overcome the limitations of mouse monoclonal antibodies. Chimerization demands the joining of the variable regions of mouse antibodies with the constant domains of human immunoglobulins that takes advantage of recombinant DNA techniques resulting in chimeric antibody derived from mouse and human antibody genes.52 Although being less immunogenic than murine monoclonal antibodies, human antichimeric antibody responses have even been reported for chimeric antibodies.53 To further reduce the undesirable immune response and confined inactivation, the mouse segment within the humanized monoclonal antibodies has been restricted to the complementarity determining regions (CDR) in CDR-grafted “humanized” antibodies.54 In order to humanize a mouse monoclonal antibody, the closest matching human immunoglobulin allotype is first identified by structural comparison.55,56 Then recombinant approaches are used to graft the CDRs from mouse hybridomas to the corresponding selected human immunoglobulin framework. As a result, the
After extensive use of anti serum therapy at the beginning of the last century it was almost abandoned until the advent of monoclonal antibodies. In general new monoclonal antibodies were approved by the FDA 10 years after the development of a new technique was reported in the literature. Palivizumab is the only monoclonal antibody currently used in the clinic that targets an infectious disease.
antibody only contains the antigen binding region from mouse origin, while the remainder of the variable and constant regions is derived from a human source.

While routine mouse monoclonal antibody production has been established, human monoclonal antibodies cannot be generated by conventional hybridoma technology, since it was not possible to found human cell lines that secrete constantly high levels of antibodies and, furthermore, humans cannot be challenged with all kind of antigens, due to ethical and safety reasons. Nowadays, phage display technology (reviewed in refs. 57-59) and transgenic mice with a human antibody locus (reviewed in ref. 60) represent established, widespread and robust technologies that allow the generation of potent human antibodies.

Phage display technologies enable in a simple to use and highly versatile procedure for the selection of antibodies against known or novel antigens. The phage display library (first description by McCafferty et al61) represents a collection of independent clones carrying a foreign DNA sequence encoding an antibody domain expressed as a fusion with the coat protein of mainly filamentous bacteriophages, as M13 or Fd (reviewed in ref. 62). Monoclonal antibody libraries can be recruited from immune fragments that are already biased towards certain specificities (encoded in the genome of immunized or infected animals or humans), or naive unbiased fragments that can be derived from nonimmune natural or semi-synthetic sources, bypassing the need for previous immunization. By applying the best suitable selection procedures, those phages that bind to the target antigen with highest affinity are retained. The phages are enriched by selective adsorption to an immobilized antigen ("panning") (reviewed in ref. 12); however various specialized screening techniques exist.57,63-65 Phage display provides the opportunity to mimic human immune response, also because of the high degree of natural variations found in the replication of the phage genomes.66 B-cell maturation in vivo requires recombination of germline gene segments accompanied with changes and mutations that can be imitated in vitro by DNA random cloning of VH and VL chain genes.67 The somatic hypermutation process that naturally contributes to the affinity maturation of antibodies can be achieved artificially by inserting point mutations into gene segments of complementarity determining regions.68,69

A method to circumvent the laborious steps of founding humanized and to obtain directly human monoclonal antibodies was developed by engineering transgenic mice with a human immunoglobulin locus as source for antibody producing hybridoma cell lines. (reviewed in ref. 60). Already in 1985 Alt et al proposed to exploit transgenic mice for the generation of therapeutic antibodies,70 and as soon as 1994 the XenoMouse* (Abgenix, Inc.)71 and the HuMAb Mouse* (Gen-Pharm-Medarex)72 were reported to be the first mice carrying both the human VH and VL repertoire created via pronuclear microinjection or yeast protoplast fusion with embryonic stem cells, respectively. For monoclonal antibody generation B-cells are isolated from immunized mice and fused to hybridomas, in a similar manner to the traditional mouse monoclonal antibody production. By employing microcell-mediated chromosome transfer—a technique capable to transfer very large fractions of the human germline—Tomizuka et al generated a chimeric mouse—TransChromo Mouse™ (TC Mouse™) carrying human chromosomes 2 and 14 regions containing the human K-light-chain and heavy-chain loci.73,74. In order to increase the low efficiency of hybridoma production due to instability of the Igk locus, the KM Mouse™ was created by cross-breeding the Kirin TC Mouse™ with the Medarex YAC-transgenic mouse.75 These mice possess the capability to carry out VDJ recombination, heavy-chain class switching and even somatic hypermutation of human antibody genes in a normal mode to generate high-affinity antibodies with completely human sequences.76 The resulting antibodies exhibit a half-life similar to natural human antibodies77 and show only differences in glycosylation patterns, thereby representing a major improvement in hybridoma technology.12 Although human monoclonal antibodies derived from transgenic mice have not yet paved their way up to FDA approval and registration, so far clinical trials with them have not revealed adverse immunogenic side events in patients.78-80 In contrast to chimeric, CDR grafted or phage display derived monoclonal antibodies,81 however there is still a need for confirming these promising data by testing transgenic mouse derived antibodies in larger subject cohorts.
The Antigenome

On the other side, the success of phage display technologies in mimicking the in vivo antibody selection process in essence has led to intensive exploration of possible improvements, mainly in the field of new display techniques. All these new selection platforms share four major steps: (1) the creation of genotypic diversity; (2) the linkage between genotype and phenotype; (3) the application of a screening procedure; and (4) the amplification of the selected binding sites.

In the Ribosome and mRNA display method, the antibody and its encoding mRNA are linked by the ribosome which is made to stop without releasing the polypeptide. The use of e.g., non-proof-reading polymerases provides additional diversity between generations and therefore represents a very successful technique in the field of antibody affinity maturation.

The attempt in displaying antibodies on the surface of different microbes has only been successful so far, when employing the yeast Saccharomyces cerevisiae. Antibodies are displayed via fusion to the α-agglutinin yeast adhesion receptor on the cell wall and selection can be accomplished via flow cytometric cell sorting. Besides yeast display, a lately described Escherichia coli based approach is currently under development.

Recently developed antibody platform technologies include retroviral display, protein-DNA display, microbead display by in vitro compartmentalization, in vivo growth selection based on protein fragment complementation and other techniques. However, their advantages over more established systems remain to be demonstrated.

One problem in the application of monoclonal antibodies lies in their restriction to a single specific epitope, limiting their ability in eliminating dynamic and evolving targets and retaining activity in the event of antigen mutation. A new generation of therapeutic antibodies that may overcome the restriction of monoclonal antibodies is the development of a recombinant poly- or oligoclonal antibody technology. For the generation of "Symphobodies"—fully human, antigen-specific recombinant polyclonal antibodies—antibody producing cells are isolated from naturally immune donor blood. cDNA encoding human heavy and light chains are amplified and linked together by Symplex PCR; pooled PCR products are then inserted into an expression vector and screened for antigen binding. Constructs expressing the selected antibodies are cloned into Chinese hamster ovary cells where they are site-specific integrated into the genome. Thus, such a development of a human antibody repertoire mirrors the human polyclonal immune response against specific antigens.

Besides the fact that the recombinant expression of antibody genes is often difficult because of their large size, the usage of whole immunoglobulins sometimes causes undesired side effects that are mediated by the Fc part of the antibody. To overcome such problems antibody fragments such as Fab, scFv, diabodies and minibodies have been engineered by removing either the entire constant region or the Fc portion. Advantages shared by these antibody fragments include their better clearance from whole body, better tissue/tumor penetration characteristics and their simple and straightforward production in bacteria bypassing mammalian cell based production. The smallest fragments are single chain fragment variables (scFv) formed by tandem arrangement of the VH and VL domains joined by a flexible linker peptide exhibiting a comparable affinity of a Fab. Their biological effects can be enhanced through linker length reduction that generates noncovalent scFv dimers "diabodies", by further shortening trimers or even tetramers can be formed. ScFvs have also been modified to deliver toxins and chemotherapeutics to various tumors by binding to cancer-associated antigens, e.g., by coupling the Pseudomonas aeruginosa exotoxin A to scFv. Linking of scFvs of different specificity creates bispecific antibodies that bind two different structures on single or different cells. Other truncated antibody variants are Minibodies—homodimers of scFv-CH3 fusion proteins—and Flex minibodies—scFv-IgG1 hinge region fusion proteins.

Whole antibody molecules can be modified as well by coupling with anti-microbial drugs. Antibodies possessing specificity to microbial antigens can be simultaneously linked to toxins, acting as immunotoxins that way. For example, Human Immunodeficiency Virus (HIV) and Cytomegalovirus specific antibodies have been linked to the ricin A chain or the Pseudomonas Exotoxin A. Unfortunately toxins can elicit immune responses limiting their repeated
therapeutic use. An alternative represents the linking of radionuclides to specific antibodies that do not need to be internalized, like toxins and are unlikely to produce significant immune responses. Radionuclide-labeled antibodies have been tested against Cryptococcus neoformans and pneumococcal infections in mice.\textsuperscript{106,107} Another development in modifying the antibody molecule was the creation of bispecific antibodies carrying two different Fab fragments and recognizing a microbial epitope for pathogen binding and at the same time a host immune component. This strategy was shown to be successful in animal models for the clearance of bacteriophages\textsuperscript{108} and P. aeruginosa.\textsuperscript{109}

The application of humanized and even fully human antibodies—is associated with low toxicity and high specificity. The benefit of high specificity is that only disease-causing pathogens are targeted and therefore the host flora should not be altered or resistant microorganisms be selected. A caveat is that pathogens with high antigenic variation may require more than one monoclonal antibody for therapy and mutants lacking the antibody determinant could emerge during treatment. Antibody molecules are highly versatile; by binding to a single determinant they can mediate various biological effects including toxin neutralization, microbial opsonization, complement activation and antibody-directed cellular cytotoxicity (Fig. 2). Antibodies can also be used to target host cells and enhance immune functions especially desirable against infectious diseases and tumors or to suppress immune responses by reducing the number of immune cells, neutralizing cytokines or blocking receptors.

\begin{figure}[h]
\begin{center}
\includegraphics[width=\textwidth]{antibody-effects.png}
\end{center}
\caption{Biological effects of antibodies in infectious disease. Antibodies neutralize viruses and toxins, block protein functions important for microbial adherence or growth, activate complement and microbial opsonization and are a prerequisite for cell-mediated cytotoxicity. All these functions together facilitate the host to combat the invading pathogen (Adapted from Casadevall et al.\textsuperscript{8})}
\end{figure}
The major disadvantages of antibody-based therapies are high costs associated with production, storage, and administration. Since antibodies have to be produced in live expression systems, the risk of contamination with prions or viruses requires continuous monitoring and testing. Additionally, antibodies have to be administered shortly after infection to be efficient, requiring rapid microbiological diagnosis. Additionally, manufacturing of Symphobodies, mimicking polyclonal antibodies in human immune response, may still have to prove that they can be obtained without chance in their composition under stable GMP conditions.

From Serum Treatment to Anti-Infective Monoclonal Antibodies

In the late 19th century Behring and Kisato discovered the efficacy of immune sera in treating infectious diseases, such as diphtheria and tetanus. In 1891 the Klemperers already protected rabbits against S. pneumoniae with immune sera showing the potential usefulness of passively administered antibodies for the treatment of pneumococcal infections. However reliable anti-pneumococcal therapy was not available until the mid 1920s, since the development of successful serum therapy required the discovery that pneumococci are genetically diverse and only type-specific sera provide protection. Improved vaccination schedules for serum donors to generate good immune responses and advanced antibody purification techniques, as well as the standardization of serum potency were necessary steps in the introduction of serum therapy (reviewed in ref. 112). The high death rate associated with meningococcal meningitis lead to fast developments also in this sector; a significant reduction of the case fatality rates was already achieved with horse sera in the early 20th century.

Serum therapy reached its heyday in the 1920s to the mid 1930s when it was standard clinical practice in the treatment of a variety of infectious diseases caused by S. pneumoniae, C. diptheriae, Neisseria meningitidis, Haemophilus influenzae, Streptococcus pyogenes and Clostridium tetani. The broad application of serum as treatment for pneumococcal disease can be estimated regarding advertisements of that time in medical journals (Fig. 3). However, with the advent of anti-microbial chemotherapy passive immunization with serum was largely abandoned for the treatment of bacterial infections due to major advantages in being less toxic, more effective and cheaper. Serum therapy was often associated with severe side effects including fever, chills and allergic reactions and delayed toxicity called "serum sickness" a syndrome associated with rash, proteinuria and arthralgia. Moreover, for satisfying efficacy precise diagnosis, appropriate and nondelayed dosage was necessary asking for physicians with considerable experience. The production of horse or rabbit therapeutic sera was very expensive because of the need for animal facilities, purification techniques, adequate storage and standardization. Nevertheless lot-to-lot variation could not be fully eliminated (reviewed in ref. 114).

Upon the arrival of the antibiotic era, anti-sera were still used for toxin-mediated disease such as botulism, tetanus and diphtheria in addition to anti-toxin therapy in the treatment of venomous snake bites. The lack of efficient anti-viral treatments also stimulated the use of antibody preparations as postexposure prophylaxis in e.g., rabies or hepatitis B (reviewed in ref. 9).

In spite of the previously experienced shortcomings, long-time neglected antibody-based therapies face a renaissance today. The description of hybridoma technology in 1975 fired researcher's imagination in developing new therapies against cancer, autoimmune or infectious diseases. As early as at the dawn of the 20th century Paul Ehrlich already dreamed about the use of antibodies as "magic bullet" for the treatment of cancer. Indeed, in the mid 1980s the first efficient use of a monoclonal antibody for the treatment of refractory lymphoma was reported. The anti-tumor effect was only temporary, since murine monoclonal antibodies have only short in vivo half-life and are immunogenic in humans; moreover they don't kill target cells forcefully due to low efficiency in complement activation and antibody dependent cell cytotoxicity. The first FDA approved murine monoclonal antibody for clinical use was OKT3 targeting CD3 in 1986 and was designed for prevention and treatment of organ rejection.

Fortunately, monoclonal antibody techniques underwent continuous and tremendous improvements in reducing the mouse derived portion of the protein and enabling the production of
Figure 3. Advertisement for serum therapy for Type I Pneumococcus. Lederle (now Wyeth) successfully sold pneumococcal treatments already in the early 20th century.
chimeric, humanized and nowadays even fully human antibodies. In the 30 years since the invention of hybridoma technique 21 monoclonal antibody therapies have been approved by the FDA (source: AdisInsight, 07.07.2006); only a single one targets an infectious disease—Palivizumab (Synagis) against respiratory syncytial virus infections.

In spite of the incredible efforts undertaken to develop novel antibody based treatments with hundreds of monoclonal antibodies being currently under preclinical development or clinical testing, only the minority of these efforts are directed against infectious targets. Among viral infections, AIDS is far the most explored area (Table 2). Due to the extreme variability of neutralizing HIV epitopes, in addition to those combating the virus particle itself,117-118 many monoclonal antibody approaches target host molecules (such as CTLA-4, CD4, LFA-1, CCR5) to hinder viral entry (reviewed ref. 119). Emerging viral infections caused by the SARS corona virus and West Nile Virus also attracted the attention of monoclonal antibody developers and several preclinical efforts are expected to enter clinical development (Table 2).

Due to the widespread appearance of multi-drug resistant bacterial pathogens and the increasing population of immuno-compromised patients, more and more efforts are focused on antibody-based strategies against pathogenic bacteria and fungi. Especially considerable efforts were and are still undertaken to treat septic shock caused by gram-negative bacteria via neutralization of endotoxin and of TNF-α induced early in the disease, unfortunately with no successful outcome so far.120-121 The most frequent microbial targets of new developments are opportunistic nosocomial pathogens, such as S. aureus and epidermidis, P. aeruginosa and Candida species (Table 1 and Table 3). The molecular targets for these monoclonal antibodies are surface structures of these pathogens, including capsular polysaccharides, cell wall glycolipids and surface proteins. The primary aim is to increase opsonophagocytic elimination of the respective organisms with the help of the host's immune cells. Unfortunately, in immuno-compromised patients (under anti-tumor treatment, organ transplantation, old age), the number of effective phagocytic cells is significantly lower than in healthy people and relying only on opsonophagocytosis may not be sufficient for cure. Monoclonal antibodies that target surface proteins and that also have essential functions in in vivo survival, multiplication (cell division, nutrient acquisition) and pathomechanisms (adhesion, cytotoxicity, immune evasion), offer another opportunity to reduce bacterial growth and ameliorate infectious damage to the host.124-127 A single chain anti-fungal antibody that was selected by the hsp90 protein of Candida albicans from antibody cDNA libraries of patients who recovered from invasive candidiasis is being developed (Mycograb). It consists of the antigen-binding variable domains of antibody heavy and light chains linked together to a recombinant protein that is expressed in E. coli. Mycograb is not dependent on recruitment of white blood cells or complement, but simply acts by binding and inhibiting hsp90 of Candida.128

Current fear of bioterrorism using biological weapons encourages the development of antibody therapies against anthrax, botulism, ebola or smallpox virus infections and aims to provide immediate immune protection through antibodies that either neutralize the pathogens and toxins themselves, or target the host by blocking corresponding receptors to prevent infection or toxicity. Recently Cohen and coworkers demonstrated the inhibition of the lethal effect of anthrax toxin via blocking of its human coreceptor, LRP6 with LRP6 specific antibodies.129

The Next Chapter of the Antibody Success Story: Bacterial Infections

In spite of the historical landmark therapy against diphtheria, antibody therapy against bacterial infections, only exceptionally, has entered the medical arena in the last 70 years. The advent of antibiotics during the forties has certainly discouraged the development of further serum treatments against bacterial pathogens.

Antibiotics have seemingly become a relatively cheap and mostly reliable weapon to control most bacterial infections and epidemics. Alongside with the increase of hygienic standards, the penetrations of mandatory childhood vaccinations and antibiotic treatment, bacterial infections seemed to be a medical problem confined only to less developed parts of the world. The cost-efficient availability, the seemingly ever growing pipeline of novel antibiotics with increasing efficacy
| Drug          | Pathogen | Antigen Target                  | Type of Antibody         | Highest Phase | Originator                  | Indication                           |
|--------------|----------|---------------------------------|--------------------------|---------------|-----------------------------|--------------------------------------|
| Palivizumab  | RSV      | RSV F glycoprotein              | Humanised mAb IgG1       | Launched      | MedImmune                  | RSV infections                       |
| Motavizumab  | RSV      | RSV F glycoprotein (derived from Palivizumab) | Humanised mAb IgG1       | III           | Eli Lilly/ MedImmune        | RSV infections                       |
| 2G12, 2F5, 4E10 | HIV      | HIV gp120, HIV gp41             | Human mAb                | II            | Polymun Scientific          | HIV infections treatment & prevention |
| hNM01        | HIV      | V(3) region of the HIV-1 envelope protein gp120 | Humanised mAb            | I             | SRD Pharmaceuticals          | HIV infections treatment             |
| HIV gp41 mAb | HIV      | HIV gp41 surface glycoprotein   | Fully human mAb          | Preclinical   | Medarex/Pfizer              | HIV infections treatment             |
| HEBIC™       | Hepatitis B | Undisclosed                  | Pooled plasma of individuals with high titers of antibody to the hepatitis B surface antigen | Launched      | Nabi Biopharmaceuticals     | Hepatitis B                           |
| Civacir™     | Hepatitis C | Undisclosed                  | Plasma of infected patients with high levels of anti-hepatitis C virus (HCV) antibodies | I             | Nabi Biopharmaceuticals, Novartis | Hepatitis C                           |
| XTL 6865     | Hepatitis C | HCV envelope E2 protein        | Fully human (derived from human immune cells of convalescent patients) | I             | XTL Biopharmaceuticals      | Hepatitis C                           |
| Anti-SARS mAb | Severe acute respiratory syndrome (SARS) | SARS coronavirus glycoprotein S | Fully human mAb          | Preclinical   | Medarex/ Massachusetts Biologic Laboratories | Coronavirus infections               |

*continued on next page*
| Drug        | Pathogen               | Antigen Target                                      | Type of Antibody      | Highest Phase | Originator       | Indication                                |
|------------|------------------------|------------------------------------------------------|------------------------|---------------|------------------|-------------------------------------------|
| Anti-SARS mAb | SARS                   | SARS coronavirus glycoprotein S                      | Fully human mAb        | Preclinical   | Crucell          | Protection against SARS virus infection |
| Anti-M2 mAb  | Influenza virus        | Influenza A M2 protein                              | Fully human mAb        | Preclinical   | Kirin/Corixa Corporation | Influenza virus infections               |
| WNV mAbs    | West Nile Virus (WNV)  | Domain II and III of WNV envelope protein            | Fully human mAb        | Preclinical   | Crucell          | WNV infections prevention and treatment  |
| Anti-rabies mAbs | Rabies              | Rabies virus glycoprotein                           | Fully human mAb        | Preclinical   | Crucell/CDC      | Rabies                                    |
| Anti-hMPV mAb | Human metapneumovirus (hMPV) | Undisclosed                                      | Undisclosed            | Preclinical   | MedImmune        | Metapneumovirus-infections               |
| Ipilimumab  | HIV                    | CTLA-4                                              | Fully human mAbs       | I             | Medarex          | HIV infections treatment, among other applications |
| TNX 355     | HIV                    | CD4 receptor                                        | Humanized mAb 5A8      | II            | Biogen Idec      | HIV infections treatment                 |
| Cytolin®    | HIV                    | 4 epitopes of the alpha sub-unit of LFA-1 (CD8)     | Murine mAb             | II            | CytoDyn          | HIV infections treatment                 |
| PRO 140     | HIV                    | Human CCR5                                          | Humanised mAb          | I             | Progenics Pharmaceuticals | HIV infections treatment                |

*continued on next page*
Table 2. Continued

| Drug | Pathogen | Antigen Target | Type of Antibody | Highest Phase | Originator | Indication |
|------|----------|----------------|------------------|---------------|------------|------------|
| CCR5mAb004 | HIV | Human CCR5 | Fully human | I | Human Genome Sciences | HIV infections treatment |
| mAb 1F7 | HIV | Idiotype common to anti-HIV and anti-SIV antibodies | Murine mAb IgMx | Preclinical | Immune Network | HIV infections treatment |
| mAb B4 | HIV | HIV receptor complex | Murine mAb | Preclinical | United Biomedical | HIV postexposure prophylaxis |
| mAb A3D8 | HIV | CD44 | Murine mAb | Preclinical | Duke University Medical Center | HIV-1 infections, myeloid leukaemia |
| CFY 196 | Rhinovirus | ICAM-1 (receptor for HRV) | Tetravalent humanised Fab fusion protein | Preclinical | Perlan Therapeutics | Rhinovirus infections |
| Anti-IFN-γ polyclonal antibody | Herpes Simplex virus (HSV) | Interferon-γ (IFN-γ) | Polyclonal antibody | I | Advanced Biotherapy | HSV infections treatment, among other applications |
| Baviluximab | Viruses | Phospholipid abnormally exposed on vascular endothelium of tumor blood vessels | Chimeric antibody | I | Peregrine Pharmaceuticals | Cancer, Hepatitis C treatment, Influenza virus infections, Viral infections |

Data were collected from the Adis R&D Insight database and homepages of listed companies in July 2006 using the world wide web. Data were grouped into: first, antibodies targeting the virus particle itself and then second, those targeting host structures. Monoclonal Antibodies are abbreviated with mAbs. This is not a complete list.
Table 3. Antibody based therapies against fungal infections

| Drug              | Pathogen                  | Antigen Target          | Type of Antibody                        | Highest Phase | Originator            | Indication                                                                 |
|-------------------|----------------------------|-------------------------|------------------------------------------|---------------|-----------------------|-----------------------------------------------------------------------------|
| Mycograb<sup>*</sup> | *Candida* spp. (C. albicans, C. krusei, C. parapsilosis, C. tropicalis) | Heat shock protein 90 (hsp90) | Human genetically recombinant antibody | Preregistration | NeuTec Pharma          | Treatment of systemic candidiasis, Cancer (e.g., Breast cancer)              |
| Candida MAb       | *Candida* spp.             | MSCRAMM<sup>®</sup> proteins | Undisclosed                              | Preclinical   | Inhibitex             | Treatment of candidiasis                                                   |
| ACE 5033          | Aspergillus fumigatus      | A. fumigatus surface protein | Fully human mAb                          | Preclinical   | ACE BioSciences, Genmab | Aspergilosis, Mycoses                                                      |
| Candida mAb       | *C. albicans*              | Corixa antigens          | Fully human mAb                          | Preclinical   | GlaxoSmithKline and Amgen | Fungal sepsis caused by *C. albicans*                                      |

Data were collected from the Adis R&D Insight database and homepages of listed companies in July 2006 using the worldwide web. Monoclonal Antibodies are abbreviated with mAbs. This is not a complete list.
invading the market has established the attitude in the medical community up into the 1970s of the last century that bacterial diseases may belong to the past. However, the emerging pattern of multidrug-resistant strains of an increasing number of pathogens in hospitals and communities has quickly ended the optimistic belief that the repertoire of anti-bacterial treatments will suffice the challenges in the infectious disease arena (for review see ref. 130). Also the discovery, development and registration of novel antibiotics have not fulfilled the too optimistic expectations that new registrations of treatments may bounce off the threat of untreatable bacterial infections (see commentaries by Clarke131 and in Biocentury132). The infiltration of genomics,133 intelligent drug design and molecular studies of bacterial host interactions in antibiotic development134 has rather led to the sobering recognition that the number of suitable targets for new anti-bacterial drugs may be rather limited.135-137 Furthermore, the often severe side affects, including allergic reactions against specific antibiotics, is restricting their applications, sometimes in critical medical conditions when they are most needed. Last, not least antibiotics often lead to lysis of bacterial cells and thereby freeing endotoxins at high levels, thereby causing overshooting immunity including sepsis.138

On the other hand before the advent of the monoclonal antibody technology, treatments of bacterial diseases with antibodies have been out of the reach of economical feasibility. Production of antibodies by immunizing animals as resorts to obtain serum is not a trivial process regarding quality, reproducibility and unwanted contaminations. Also as one has experienced with whole cell bacterial vaccines, immunization with in vitro grown pathogens may not lead to the type of specific antibodies that neutralize them, since they may not display the proper antigens at the surface. Thus, the progress made in defining disease specific antigens for vaccine development has provided novel tools to raise highly specific antibodies that may prevent or block bacterial infections or at least supporting the recovery process.

The skepticism in the medical and scientific community towards the paradigm of anti-infective anti-bacterial monoclonal antibodies is nurtured by multiple lines of thoughts:
1. Existing treatments are sufficient to control bacterial diseases.
2. Monoclonal antibody therapy may not find its way into treatment schedules that would justify the costs.
3. A single monoclonal antibody directed against a specific antigen per se may not be able to counteract the pathogenic course of a bacterial infection.

While all three arguments are widely accepted, a closer look into the paradigm discloses that they are not necessarily substantiated, if one considers the medical need, the progress made in identification of suitable antigenic targets and the positive experience of using monoclonal antibodies against e.g., malignant diseases (reviewed in ref. 139).

The medical need is given, whenever conventional treatment and prophylaxis are not available. S. aureus in context with nosocomial infections is equally a target for antibody treatments as Pneumococcus, both representing problem germs in intensive care (Table 4).

Moreover, costs for antibody treatments in connection with above described infectious disease outbreaks often missing adequate medical treatments appear to be not too dramatic, if one relates them to the hospital conditions and the underpinning economical efforts spent. Last but not least, the increasingly wide usage of monoclonal antibodies outside of the infections disease area has certainly aided in lowering the costs of development and manufacturing, thereby paving the way to novel treatments.3

The question remains what kind of features form the prerequisites for a monoclonal antibody in order to be able to counteract a bacterial infection? The answer to this problem lies—to our opinion—in the selection of the best suitable antigenic targets for the development of monoclonal antibodies. The antigens should be expressed on the pathogen surface during the infectious process; preferred throughout the most important stages of disease manifestation: i.e., during colonization, spreading and invasion. Also the antigens of choice should have a proven record to be a target of antibodies from individuals who have encountered the pathogen with positive or protective outcome. In addition, the selected antigens should be conserved among all clinical strains of the germ causing the underpinning infections.
| Pathogen         | Disease                                                                 | Target Group                                           | Incidence                                      | Medical Need                                      |
|------------------|-------------------------------------------------------------------------|--------------------------------------------------------|------------------------------------------------|-------------------------------------------------|
| Nosocomial       | Sepsis, bacteremia, pneumonia, wound and surgical site infection, osteomyelitis, urinary tract infections | Hospitalized (esp. elderly, immunocompromized)         | Nosocomial infections: 2 million/yr/US; 1 of 20 hospital admissions; 100,000 death/yr/US | High incidence; High medical costs (20 Bn$/yr in dev. World); Increasing antibiotic resistance |
| S. aureus        | Sepsis, bacteremia                                                     | Premature newborns, <34th pregnancy week               | 1-2/1000 life birth                           | High mortality; Support the premature immune system |
| S. aureus        | Sepsis, bacteremia, pneumonia, wound infection, osteomyelitis          | Hospitalized, esp. surgery patients                    | 25% of nosocomial infections                  | High mortality; High incidence; High medical costs |
| S. pneumoniae/   | Bacteremia                                                              | Community acquired, elderly                            | ~75,000/yr/US                                 | High mortality; Multi-drug resistance             |
| Pneumococcus     | Pneumonia                                                               |                                                        | ~500,000/yr/US                                | High mortality; High incidence; High medical costs |
| S. pneumoniae/   | Meningitis                                                              |                                                        | ~5,000/yr/US                                  | Antibiotic resistance; Support the premature immune system; Increasing ab resistance |
| Group B Strep/   | Bacteremia, pneumonia, meningitis                                       | Premature newborns, <34th pregnancy week               | 1-2/1000 life birth                           | High mortality; High medical costs; Multi-drug resistance |
| S. agalactiae    | wound infection, bacteremia, sepsis                                     | Intensive care, burn patients                          | 80% of 2nd and 3rd grade burn patients        | High mortality; High medical costs; Multi-drug resistance; High mortality, high medical costs |
| P. aeruginosa    | Pneumonia, sepsis                                                      | Intensive care, artificially ventilated                | 15-20% of HAP and 80% of VAP                 | High medical costs; Multi-drug resistance; Multi-drug resistance, high mortality, high medical costs |
| E. faecalis and  | Sepsis, bacteremia, endocarditis                                        | Abdominal surgery patients                             | 10% of nosocomial infections                  | Mortality, multi-drug resistance (E. faecium)     |
| faecium          |                                                                         |                                                        |                                                | Multi-drug resistance                            |
| Klebsiella       | Nosocomial pneumonia                                                    | Hospitalized (esp. elderly, immunocompromized)         | 10% of nosocomial infections                  |                                                |
| pneumoniae       |                                                                         |                                                        |                                                | Multi-drug resistance                            |

Hospital associated pneumonia (HAP) makes up 5-10/1000 hospital admissions and ventilation associated pneumonia (VAP) accounts for 80% of all HAP. Hospitalized burn patients average out 50,000 per year in the US. Of all approximately 9 million life births in the US and Europe per year premature birth before the 36th week accounts for 25% and premature birth before the 34th week for 10%.
All up to here listed features of target antigens may suffice the need to detect the intruder with a monoclonal antibody, particularly if the bound antibody funnels the bacterium into the immunological decontamination program, e.g., opsonization. On the other hand, the lesson learnt from antibiotics is that they have to kill the pathogen or at least disable bacterial growth in the host. In the light of the notion that prevention or treatment of a bacterial infection with monoclonal antibodies may be restricted to a single antibody, one would aim the target antigen also to exert a function needed for bacterial survival in the host. Thus, the antibody will neutralize a virulence factor or an enzyme needed in the infections life cycle of the pathogen. Such a dual mode of action resembles the features of monoclonal antibodies employed in cancers therapy: these antibodies seem to block cancerous cells by marking them for the immunological destruction, but also by blocking their growth. Thus, monoclonal antibodies need to be directed against carefully selected antigenic targets in order to achieve an optimum of interference with bacterial survival in the host.

The recently invented antigen identification procedure that is designed to establish the “antigenome” of pathogens has been instrumental in the development of novel bacterial subunit vaccines. Characterization of a S. aureus antigen derived from the antigenome—that is presently used in preclinical and clinical programs—has indeed revealed its involvement in virulence and survival function.

The feasibility of antigens to serve as targets for monoclonal antibody treatments can be pretested in vaccine models where protection of pathogen-challenged animals is assessed. There is no doubt in mind that antigens giving the wanted protection in a vaccine model may not be sufficient when employed for the development of anti-infective antibodies. However, the potency of an antigen in providing protective immunity as vaccine may be a positive and sufficient selective criterion, alongside with all the other features that have been described for antigens selected for subunit vaccine development.

References
1. Patti JM. Immunotherapeutics for nosocomial infections. Expert Opin Investig Drugs 2004; 13(6):673-9.
2. Tenover FC. Mechanisms of anti-microbial resistance in bacteria. Am J Med 2006; 119(6 Suppl 1):S3-10; discussion S62-70.
3. Lipsitch M, Samore MH. Antimicrobial use and anti-microbial resistance: a population perspective. Emerg Infect Dis 2002; 8(4):347-54.
4. Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163(9):1009-21.
5. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 2002; 8(8):833-41.
6. Riedel S. Anthrax: a continuing concern in the era of bioterrorism. Proc (Bayl Univ Med Cent) 2005; 18(3):234-43.
7. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies reexamined. Lancet Infect Dis 2002; 2(6):327-43.
8. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2(9):695-703.
9. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13(4):602-14.
10. Fry BG, K. D. Winkel, J. C. Wickramaratna et al. Effectiveness of Snake Antivenom: Species and Regional Venom Variation and Its Clinical Impact. Journal of Toxicology 2003; 22(1):23-34.
11. Watt CH. Poisonous snakebite treatment in the United States. JAMA 1978; 240(7):654-6.
12. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005; 20(1):17-29.
13. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6(5):343-57.
14. Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005; 1(2):221-34.
15. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for anti-tumor therapy. Cancer Invest 1991; 9(5):553-62.
16. Adams GF, Weitner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23(9):1147-57.
17. Anderson EL, Kennedy DJ, Geldmacher KM et al. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996; 128(5 Pt 1):649-53.
18. Impact-RSV_Sudy_Group. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 1998; 102(5):1211-6.

19. Meinke A, Henics T, Nagy E. Bacterial genomes pave the way to novel vaccines. Curr Opin Microbiol 2004; 7(3):314-20.

20. Meinke A, Henics T, Hanner M et al. Antigene technology: a novel approach for the selection of bacterial vaccine candidate antigens. Vaccine 2005; 23(17-18):2035-41.

21. Henics T, Winkler B, Pfeifer U et al. Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens. Biotechniques 2003; 35(1):196-202, 204, 206 passim.

22. Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 2002; 99(10):6573-8.

23. Kulkin NA, Clark DJ, Secure S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74(4):2215-23.

24. Ayliffe GA. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997; 24 Suppl 1:S74-9.

25. Weinstein W; Roe M, Towns M et al. Resistant enterococci: a prospective study of prevalence, incidence and factors associated with colonization in a university hospital. Infect Control Hosp Epidemiol 1996; 17(1):36-41.

26. Zagursky RJ, Olmsted SB, Russell DP et al. Bioinformatics: how it is being used to identify bacterial vaccine candidates. Expert Rev Vaccines 2003; 2(3):417-36.

27. Adu-Bobie J, Capecci B, Serruto D et al. Two years into reverse vaccinology. Vaccine 2003; 21(7-8):605-10.

28. Lei B, Liu M, Chesney GL et al. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. J Infect Dis 2004; 189(1):79-89.

29. Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002; 184(19):5479-90.

30. Cockie PJ, Gordon SV, Lalvani A et al. Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect Immun 2002; 70(12):6996-7003.

31. Mayers C, Duffield M, Rowe S et al. Analysis of known bacterial protein vaccine antigens reveals biased physical properties and amino acid composition. In: Comparative and Functional Genomics: New York: John Wiley and Sons, Ltd: 2003: 468-478.

32. De Groot AS. Sbai H, Aubin CS et al. Immunoinformatics: Mining genomes for vaccine components. Immunol Cell Biol 2002; 80(3):255-69.

33. Flower DR. Towards in silico prediction of immunogenic epitopes. Trends Immunol 2003; 24(12):667-74.

34. Tettelin H, Masignani V, Cieslewicz MJ et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci USA 2002; 99(19):12391-6.

35. Maione D, Margarit I, Rinaudo CD et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005; 309(5731):148-50.

36. Conway T, Schoolnik GK. Microarray expression profiling: capturing a genome-wide portrait of the transcriptome. Mol Microbiol 2003; 47(4):879-89.

37. Werner T. Proteomics and regulomics: the yin and yang of functional genomics. Mass Spectrom Rev 2004; 23(1):25-33.

38. Voyich JM, Sturdevant DE, Braughton KR et al. Genome-wide protective response used by group A Streptococcus to evade destruction by human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 2003; 100(4):1996-2001.

39. Fisher MA, Plikaytis BB, Shinnick TM. Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol 2002; 184(14):4025-32.

40. Grifantini R, Bartolini E, Muzzi A et al. Gene expression profile in Neisseria meningitidis and Neisseria lactamica upon host-cell contact: from basic research to vaccine development. Ann NY Acad Sci 2002; 975:202-16.

41. Werner T. Proteomics and regulomics: the yin and yang of functional genomics. Mass Spectrom Rev 2004; 23(1):25-33.

42. Haas G, Karalli G, Ebermayer K et al. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2002; 2(3):313-24.

43. Cole JN, Ramirez RD, Currie BJ et al. Surface analyses and immune reactivities of major cell wall-associated proteins of group a streptococcus. Infect Immun 2005; 73(5):3137-46.
44. Rodriguez-Ortega MJ, Norais N, Bensi G et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24(2):191-7.

45. Vytvytska O, Nagy E, Bluggel M et al. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2002; 2(5):580-90.

46. Ariel N, Zvi A, Makarova KS et al. Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun 2003; 71(8):4563-79.

47. Hughes MJ, Moore JC, Lanz JD et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 2002; 70(3):1254-9.

48. The Word: Pathosphere, New Scientist 2005; 2520:58.

49. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517):495-7.

50. Idee GG. Human anti-mouse antibodies. Arch Pathol Lab Med 2000; 124(6):921-3.

51. Ober R, Radu CG, Ghetie V et al. Differences in promiscuity for antibody-FeRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13(12):1551-9.

52. Ariel N, Zvi A, Makarova KS et al. Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun 2003; 71(8):4563-79.

53. Hughes MJ, Moore JC, Lanz JD et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 2002; 70(3):1254-9.

54. The Word: Pathosphere, New Scientist 2005; 2520:58.

55. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517):495-7.

56. Idee GG. Human anti-mouse antibodies. Arch Pathol Lab Med 2000; 124(6):921-3.

57. Ober R, Radu CG, Ghetie V et al. Differences in promiscuity for antibody-FeRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13(12):1551-9.

58. Ariel N, Zvi A, Makarova KS et al. Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun 2003; 71(8):4563-79.

59. Hughes MJ, Moore JC, Lanz JD et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 2002; 70(3):1254-9.

60. The Word: Pathosphere, New Scientist 2005; 2520:58.

61. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517):495-7.
74. Ishida I, Tomizuka K, Yoshida H et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4(1):91-102.
75. Ishida I, Tomizuka K. Yoshida H et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4(1):91-102.
76. Harding FA, Lonberg N. Class switching in human immunoglobulin transgenic mice. Ann NY Acad Sci 1995; 764:536-46.
77. Yang XD, Corvalan JR, Wang P et al. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutic treatments for inflammatory disease states. J Leukoc Biol 1999; 66(3):401-10.
78. Foon KA, Yang XD, Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58(3):984-90.
79. Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19(7):1059-66.
80. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100(14):8372-7.
81. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003; 5(2):172-9.
82. Lipovsek D, Pluckthun A. In vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 2004; 290(1-2):51-67.
83. Mattheakis LC, Bhart RR, Dower WJ. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci USA 1994; 91(19):9022-6.
84. He M, Taussig MJ. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particle for in vitro display and evolution of antibody combining sites. Nucleic Acids Res 1997; 25(24):5132-4.
85. Hanes J, Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997; 94(10):4937-42.
86. Hanes J, Schaffitzel C, Knappe A et al. Picomolar affinity antibodies from a fully synthetic naïve library selected and evolved by ribosome display. Nat Biotechnol 2000; 18(12):1287-92.
87. Boder ET, Witttrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15(6):553-7.
88. Harvey BR, Georgiou G, Hayhurst A et al. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci USA 2004; 101(25):9193-8.
89. Urban JH, Schneider RM, Compte M et al. Baldwin D, Vallina L, et al. Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res 2005; 33(4):e35.
90. Reiersen H, Loberski I, Loset GA et al. Covalent antibody display—a new method for cloning and selection of functional human antibodies. Nucleic Acids Res 2005; 33(1):e10.
91. Sepp A, Tawfik DS, Griffiths AD. Microbead display by in vitro compartmentalization: selection for binding using flow cytometry. FEBS Lett 2002; 532(3):455-8.
92. Moseer E, Koch H, Pluckthun A. Fast selection of antibodies without antigen purification: adaptation of the protein fragment complementation assay to select antigen-antibody pairs. J Mol Biol 2001; 308(2):115-22.
93. Urech DM, Liechten P, Barberis A. Cell growth selection system to detect extracellular and transmembrane protein interactions. Biochim Biophys Acta 2003; 1622(2):117-27.
94. Haurum J, Bregenholt S. Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle. IDrugs 2005; 8(5):409.
95. Bird RE, Walker BW. Single chain antibody variable regions. Trends Biotechnol 1991; 9(4):132-7.
96. Ketkut AA, Malby RL, Caldwell JB et al. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur J Biochem 1994; 221(1):151-7.
97. Helliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90(14):6444-8.
98. Ketkut AA, Lah M, Oddie GW et al. Single-chain Fv fragments of anti-neurominidase antibody NC10 containing five and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng 1997; 10(4):423-33.
99. Le Gall F, Kipriyanov SM, Moldenhauer G et al. Dis-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 1999; 453(1-2):164-8.
100. Di Paolo C, Willuda J, Kubetzko S et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective anti-tumor activity. Clin Cancer Res 2003; 9(7):2837-48.
101. Korn T, Muller R, Kontermann RE. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 2004; 27(2):99-106.

102. Hu S, Shively L, Raubitschek A et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56(13):3055-61.

103. Barnett BB, Smeee DF, Malek SM et al. Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells. Antimicrob Agents Chemother 1996; 40(2):470-2.

104. Till MA, Zolla-Pazner S, Gorny MK et al. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci USA 1989; 86(6):1987-91.

105. McHugh L, Hu S, Lee BK et al. Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. J Biol Chem 2002; 277(37):34383-90.

106. Dadachova E, Bryan RA, Frenkel A et al. Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob Agents Chemother 2004; 48(3):1004-6.

107. Dadachova E, Burns T, Bryan RA et al. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother 2004; 48(5):1624-9.

108. Taylor RP, Martin EN, Reinagel ML et al. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol 1997; 159(8):4035-44.

109. Lindorfer MA, Nardin A, Foley PL et al. Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J Immunol 2001; 167(4):2240-9.

110. Behring EA, Kisato, S. Ueber das zustandekommen der dipherie-immunität und der tetanus-immunität bei thieren. Deutsch. Med. Woch. 1890; 49:1113-1114.

111. Klemperer G, Klemperer, F. Versuche ueber immunisirung und heilung bei der pneumokokkeninfektion. Berlin Klin. Wochenschr. 1891; 28:833-835.

112. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38(8):1695-702.

113. Flexner S, Jobling, J. W. Serum treatment of epidemic cerebro-spinal meningitis. The Journal of Experimental Medicine 1908; 10:141-195.

114. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 1996; 2(3):200-8.

115. Nadler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40(9):3147-54.

116. Wilde MJ, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51(5):865-94.

117. Steigler G, Katunger H. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J Antimicrob Chemother 2003; 51(4):757-9.

118. Montefiori DC. Neutralizing antibodies take a swipe at HIV in vivo. Nat Med 2005; 11(6):593-4.

119. Markovic I, Clouse KA. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2004; 2(3):223-34.

120. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326(17):1153-7.

121. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999; 25(6):556-66.

122. Reinhart K, Karrai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29(7 Suppl):S121-5.

123. Manocha S, Feinstein D, Kumar A. Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs 2002; 11(12):1795-812.

124. Burnie JP, Brooks W, Donohoe M et al. Defining antibody targets in Streptococcus oralis infection. Infect Immun 1996; 64(5):1600-8.

125. Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial anti-fungal therapy. Vaccine 2004; 22(7):865-71.
129. Wei W, Lu Q, Chaudry GJ, Leplla SH, Cohen SN. The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell 2006; 124(6):1141-54.
130. Walsh C. Antibiotics: Actions, Origins, Resistance: ASM Press; 2003.
131. Clarke T. Drug companies snub antibiotics as pipeline threatens to run dry. Nature 2003; 425(6955):225.
132. Biocentury. The Bernstein report. 2006:p. A2 of 23.
133. Pucci MJ. Use of genomics to select anti-bacterial targets. Biochem Pharmacol 2006; 71(7):1066-72.
134. Marra A. Can virulence factors be viable anti-bacterial targets? Expert Rev Anti Infect Ther 2004; 2(1):61-72.
135. Becker D, Selbach M, Rollenhagen C et al. Robust Salmonella metabolism limits possibilities for new anti-microbials. Nature 2006; 440(7082):303-7.
136. Schmidt FR. The challenge of multidrug resistance: actual strategies in the development of novel anti-bacterials. Appl Microbiol Biotechnol 2004; 63(4):335-43.
137. Hughes D. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat Rev Genet 2003; 4(6):432-41.
138. Holzheimer RG. Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother 2001; 13 Spec No 1(1):159-72.
139. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54(1):11-29.
140. Mazmanian SK, Skaar EP, Gaspar AH et al. Passage of heme-iron across the envelope of Staphylococcus aureus. Science 2003; 299(5608):906-9.
141. Fleuridor R, Zhong Z, Pirofiski L. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptocoecosis. J Infect Dis 1998; 178(4):1213-6.
142. Pier GB, Boyer D, Preston M et al. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol 2004; 173(9):5671-8.
143. Barnea Y, Carmeli Y, Gur E et al. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model. Plast Reconstr Surg 2006; 117(7):2284-91.
144. Neville LF, Barnea Y, Hammer-Munz O et al. Antibodies raised against N’-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection. Int J Mol Med 2005; 16(1):165-71.
145. Kling DE, Gravekamp C, Madoff LC et al. Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus. Infect Immun 1997; 65(4):1462-7.
146. Bevanger L, Naess AI. Mouse-protective antibodies against the Lbc proteins of group B streptococci. Acta Pathol Microbiol Immunol Scand [B] 1985; 93(2):121-4.
147. Michel JL, Madoff LC, Kling DE et al. Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun 1991; 59(6):2023-8.
148. Martin D, Rioux S, Gagnon E et al. Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun 2002; 70(9):4897-901.
149. Park HS, Clevy PP. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005; 73(12):7878-86.
150. Connolly SE, Benach JL. Cutting edge: the spirochetemia of murine relapsing fever is cleared by complement-independent bactericidal antibodies. J Immunol 2001; 167(6):3029-32.
151. Beedham RJ, Turnbull PC, Williamson ED. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 2001; 19(31):4409-16.
152. Little SF, Iwins BE, Fellows PF et al. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997; 65(12):5171-5.
153. Blanpain C, Libert F, Vassart G et al. CCR5 and HIV infection. Receptors Channels 2002; 8(1):19-31.
154. Vernachio JH, Bayer AS, Ames B et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 2006; 50(2):511-8.